 |
|
|
 |
|
Client
- A top 10 diversified healthcare company
Critical Challenges
- 12-year old antihypertensive drug with a rapidly
eroding trend line and
declining revenue
- Competition gaining momentum
- Competing with newer, more innovative treatments
for this
disease state
Objectives
- Sustain sales volume and maximize remaining financial
potential of mature product
- Provide comprehensive brand management, including
fundamental market analyses, positioning and strategy
- Develop and implement significant promotional materials
to
support strategy
Solution
- Assume full responsibility for product sales and
marketing, and shared responsibility for trade relations
strategy
- Deploy an aggressive field force to maintain SOV
with key targets
- Introduce new tactical programs, including E-sample
vouchers
Results
- Erosion rate significantly reduced
- Client earned $103 million in incremental revenue
during program
- Delivered substantial increases in percent of TRx's
over contractual goals for three consecutive years
- 2001 (starting May): +3%
- 2002: +14%
- 2003: +32%
- Exceeded 2003 Rx contractual goal of 10.1 million
by approximately 1 million TRx's
|
|
Product
Antihypertensive
DATA
PDI consistently exceeded the contractual baseline over
a 3-year period, earning the client $103 million in incremental
revenue.
Source: Verispan. PDI data
on file.
|
 |
|
|